Fig. 5

Dasatinib inhibits AKT and/or ERK phosphorylation to regulate LPS-induced proinflammatory cytokine levels in BV2 microglial cells. a BV2 microglial cells were treated with MK2206 (AKT inhibitor, 10 μM) or vehicle (1% DMSO) for 30 min, treated with vehicle (1% DMSO) or dasatinib (250 nM) for 30 min, and treated with PBS or LPS (1 μg/ml) for 5 h. RT-PCR was then performed to measure proinflammatory cytokine levels. b, c Quantification of the data in a (COX-2: con, n = 11; LPS, n = 11; dasatinib+LPS, n = 11; MK2206+LPS, n = 11; MK2206+dasatinib+LPS, n = 11; and IL-6: con, n = 8; LPS, n = 8; dasatinib+LPS, n = 8; MK2206+LPS, n = 8; MK2206+dasatinib+LPS, n = 8). d BV2 microglial cells were treated with PD98059 (ERK inhibitor, 10 μM) or vehicle (1% DMSO) for 30 min, treated with vehicle (1% DMSO) or dasatinib (250 nM) for 30 min, and treated with PBS or LPS (1 μg/ml) for 5 h. RT-PCR was then performed. e, f Quantification of the data in d (COX-2: con, n = 7; LPS, n = 7; dasatinib+LPS, n = 7; PD98059+LPS, n = 7; PD98059+dasatinib+LPS, n = 7; and IL-6: con, n = 11; LPS, n = 11; dasatinib+LPS, n = 11; PD98059+LPS, n = 11; PD98059+dasatinib+LPS, n = 11). One-way ANOVA with Tukey’s post hoc test was used to analyze significant differences. *p < 0.05, ***p < 0.001